Transforming genetic discoveries into groundbreaking treatments
We are accelerating the journey from genetic discovery to groundbreaking therapies in neurology, autoimmune diseases, and inflammatory skin conditions.
A Global Research Network —
Our R&D efforts are augmented by a world-class ecosystem of leading experts, scientists, and research institutions, collaborating to drive genomics-informed breakthroughs in neurology, dermatology, immunology, and inflammation.
The Pulse
-
AKUREYRI, ICELAND AND PHILADELPHIA, PA – JULY 23, 2026 – A consortium of European and US-based investors and Nobias Therapeutics today announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage biotechnology company dedicated to advancing SYN-001 for the treatment of neuropsychiatric symptoms associated with 22q11DS. With the acquisition of Nobias Therapeutics’…
